Condition: Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors · Sponsor: Novartis Pharmaceuticals
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision has already been made to be treated with dabrafenib and trametinib, irrespective of the trial participation.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Lundquist Inst BioMed at Harbor | Torrance, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Denver, Colorado, United States | Recruiting |
| Johns Hopkins University | Washington D.C., District of Columbia, United States | Recruiting |
| Duke Clinical Research Institute | Durham, North Carolina, United States | Recruiting |
| Oncology Hematology Care Inc | Cincinnati, Ohio, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Recruiting |
| El Paso Texas Oncology | El Paso, Texas, United States | Recruiting |
| Texas Oncology San Antonio | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05868629